AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Coya Therapeutics, Inc. Director's Dealing 2025

Jan 13, 2025

34219_dirs_2025-01-13_3bc10559-32bb-4fda-9a02-e5c929613344.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Coya Therapeutics, Inc. (COYA)
CIK: 0001835022
Period of Report: 2025-01-09

Reporting Person: Grossman Fred (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-09	Stock Option (right to buy)	$6.07	A	140562	Acquired	2035-01-09	Common Stock, par value $0.0001 per share (140562)	Direct

Footnotes

F1: The option will vest in monthly installments over 36 months commencing on February 9, 2025, subject to continuous service on each vesting date.